数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Daniel K. Podolsky Director 70 35.76万美元 未持股 2024-05-01
Mala Anand Director 56 33.18万美元 1.11 2024-05-01
Heidi Kunz Director 69 1635.53万美元 0.17 2024-05-01
Otis W. Brawley Director 64 34.27万美元 未持股 2024-05-01
George A. Scangos Director 76 36.76万美元 1.79 2024-05-01
Koh Boon Hwee Director 73 50.26万美元 4.58 2024-05-01
Mikael Dolsten Director 65 35.76万美元 0.20 2024-05-01
Dow R. Wilson Director 65 37.26万美元 未持股 2024-05-01
Sue H. Rataj Director 66 35.76万美元 2.49 2024-05-01
Hans E. Bishop Director 60 34.76万美元 未持股 2024-05-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Padraig McDonnell Chief Commercial Officer and President,Chief Operating Officer and CEO-elect 53 327.29万美元 1.49 2024-05-01
Dominique P. Grau Senior Vice President, Human Resources and Global Communications 65 221.28万美元 未持股 2024-05-01
Robert W. McMahon Vice President and Chief Financial Officer 55 481.03万美元 9.29 2024-05-01
Rodney Gonsalves Vice President, Corporate Controllership and Chief Accounting Officer 59 未披露 未持股 2024-05-01
Michael Tang Senior Vice President, General Counsel and Secretary 50 243.97万美元 未持股 2024-05-01
Phil Binns Senior Vice President, Agilent and President, Life Sciences and Applied Markets Group 62 未披露 未持股 2024-05-01
Henrik Ancher Jensen Senior Vice President, Agilent and President, Order Fulfillment and Supply chain 59 333.43万美元 0.93 2024-05-01

董事简历

中英对照 |  中文 |  英文
Daniel K. Podolsky

Daniel K. Podolsky, 自2008年9月起担任the University of Texas Southwestern Medical Center(大型学术医疗中心,患者看护提供商,研究机构)的总裁;此前兼任Harvard Medical School的医学Mallinckrodt教授,以及Massachusetts General Hospital的胃肠病学主治医师;2005年至2008年间担任Partners Healthcare System, Inc.(非营利性医疗保健系统,面向患者护理、研究、教授和服务)的首席学术官兼学术项目主管。他 holds the Philip O’Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science。 他是the Institute of Medicine of the US National Academy of Sciences的成员, the Southwestern Medical Foundation的董事,也是Antibe Therapeutics, Inc.(关注炎症、疼痛和/或血管机能障碍引起的疾病的治疗)的科学顾问。他也是the National Academies of Sciences军事学和技术的董事。


Daniel K. Podolsky,has served as President of the University of Texas Southwestern Medical Center, a leading academic medical center, patient care provider and research institution, since September 2008. Previously Dr. Podolsky also served concurrently as Mallinckrodt Professor of Medicine at Harvard Medical School and the Chief of Gastroenterology at Massachusetts General Hospital. From 2005 to 2008, Dr. Podolsky served as Chief Academic Officer and Faculty Dean, Academic Programs of Partners Healthcare System, Inc., a non-profit health care system committed to patient care, research, teaching and service. Dr. Podolsky holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Board of the Southwestern Medical Foundation.
Daniel K. Podolsky, 自2008年9月起担任the University of Texas Southwestern Medical Center(大型学术医疗中心,患者看护提供商,研究机构)的总裁;此前兼任Harvard Medical School的医学Mallinckrodt教授,以及Massachusetts General Hospital的胃肠病学主治医师;2005年至2008年间担任Partners Healthcare System, Inc.(非营利性医疗保健系统,面向患者护理、研究、教授和服务)的首席学术官兼学术项目主管。他 holds the Philip O’Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science。 他是the Institute of Medicine of the US National Academy of Sciences的成员, the Southwestern Medical Foundation的董事,也是Antibe Therapeutics, Inc.(关注炎症、疼痛和/或血管机能障碍引起的疾病的治疗)的科学顾问。他也是the National Academies of Sciences军事学和技术的董事。
Daniel K. Podolsky,has served as President of the University of Texas Southwestern Medical Center, a leading academic medical center, patient care provider and research institution, since September 2008. Previously Dr. Podolsky also served concurrently as Mallinckrodt Professor of Medicine at Harvard Medical School and the Chief of Gastroenterology at Massachusetts General Hospital. From 2005 to 2008, Dr. Podolsky served as Chief Academic Officer and Faculty Dean, Academic Programs of Partners Healthcare System, Inc., a non-profit health care system committed to patient care, research, teaching and service. Dr. Podolsky holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Board of the Southwestern Medical Foundation.
Mala Anand

Mala Anand 自 2019 年 11 月起担任 Microsoft 客户体验企业副总裁。在加入 Microsoft 之前,她于 2016 年 10 月至 2019 年 10 月担任 SAP SE 智能企业解决方案和行业总裁。从 2014 年 7 月至 2016 年 10 月,Ms. Anand 于 2007 年 10 月至 2014 年 6 月担任 Cisco Systems, Inc. 的数据与分析和自动化软件平台组高级副总裁,并担任 Cisco 服务平台组的副总裁兼总经理,她拥有多项技术专利。 在此之前,Anand 女士在软件产品、上市、服务和技术业务方面担任过多个高级管理职位,并曾担任风险投资公司 Kleiner Perkins Caufield and Byers 的常驻企业家。 她拥有马萨诸塞大学计算机科学学士学位和布朗大学计算机科学硕士学位。


Mala Anand,has served as Corporate Vice President, Customer Experience of Microsoft since November 2019. Prior to joining Microsoft, she served as President, Intelligent Enterprise Solutions and Industries of SAP SE from October 2016 to October 2019. From July 2014 to October 2016, Ms. Anand served as Senior Vice President, Data & Analytics and Automation Software Platform group at Cisco Systems, Inc. and as Vice President and General Manager, Services Platform Group at Cisco from October 2007 to June 2014, and she holds multiple technology patents. Prior to that, Ms. Anand held various senior executive positions in software products, go-to-market, services, and technology businesses and served as entrepreneur in residence for Kleiner Perkins Caufield and Byers, a venture capital firm. She holds a bachelor's degree in computer science from the University of Massachusetts and a master's degree in computer science from Brown University.
Mala Anand 自 2019 年 11 月起担任 Microsoft 客户体验企业副总裁。在加入 Microsoft 之前,她于 2016 年 10 月至 2019 年 10 月担任 SAP SE 智能企业解决方案和行业总裁。从 2014 年 7 月至 2016 年 10 月,Ms. Anand 于 2007 年 10 月至 2014 年 6 月担任 Cisco Systems, Inc. 的数据与分析和自动化软件平台组高级副总裁,并担任 Cisco 服务平台组的副总裁兼总经理,她拥有多项技术专利。 在此之前,Anand 女士在软件产品、上市、服务和技术业务方面担任过多个高级管理职位,并曾担任风险投资公司 Kleiner Perkins Caufield and Byers 的常驻企业家。 她拥有马萨诸塞大学计算机科学学士学位和布朗大学计算机科学硕士学位。
Mala Anand,has served as Corporate Vice President, Customer Experience of Microsoft since November 2019. Prior to joining Microsoft, she served as President, Intelligent Enterprise Solutions and Industries of SAP SE from October 2016 to October 2019. From July 2014 to October 2016, Ms. Anand served as Senior Vice President, Data & Analytics and Automation Software Platform group at Cisco Systems, Inc. and as Vice President and General Manager, Services Platform Group at Cisco from October 2007 to June 2014, and she holds multiple technology patents. Prior to that, Ms. Anand held various senior executive positions in software products, go-to-market, services, and technology businesses and served as entrepreneur in residence for Kleiner Perkins Caufield and Byers, a venture capital firm. She holds a bachelor's degree in computer science from the University of Massachusetts and a master's degree in computer science from Brown University.
Heidi Kunz

Heidi Kunz自2019年9月起担任Phathom Pharmaceuticals, Inc.的董事。从2003年9月到2012年12月退休,她担任Blue Shield of California的执行副总裁兼首席财务官。在加入Blue Shield of California之前,1999年至2003年1月,她担任Gap, Inc.的执行副总裁兼首席财务官。从1995年到1999年,她担任ITT Industries, Inc.的首席财务官。她还在通用汽车公司担任高级财务管理职务,包括从1979年到1995年的16年任期内担任副总裁和财务主管。她目前担任Agilent Technologies Inc.(全球科学仪器制造和临床诊断公司)和Avanos Medical, Inc.(公共医疗设备公司)的董事,此前担任Financial Engines, Inc.(投资咨询公司)的董事。她持有哥伦比亚商学院(Columbia Business School)的金融和会计工商管理硕士学位,以及乔治城大学(Georgetown University)的俄语学士学位。


Heidi Kunz,has served as a member of the Board of Directors of Phathom Pharmaceuticals, Inc. since September 2019. She is a member of the Board of Directors of Icosavax, Inc. since May 2021. She has served as Executive Vice President and Chief Financial Officer of Blue Shield of California from 2003 through 2012 and as Executive Vice President and the Chief Financial Officer of Gap, Inc. from 1999 to 2003. Prior thereto, Ms. Kunz served as the Chief Financial Officer of ITT Industries, Inc. from 1995 to 1999. From 1979 to 1995, she held senior financial management positions at General Motors Corporation, including Vice President and Treasurer.
Heidi Kunz自2019年9月起担任Phathom Pharmaceuticals, Inc.的董事。从2003年9月到2012年12月退休,她担任Blue Shield of California的执行副总裁兼首席财务官。在加入Blue Shield of California之前,1999年至2003年1月,她担任Gap, Inc.的执行副总裁兼首席财务官。从1995年到1999年,她担任ITT Industries, Inc.的首席财务官。她还在通用汽车公司担任高级财务管理职务,包括从1979年到1995年的16年任期内担任副总裁和财务主管。她目前担任Agilent Technologies Inc.(全球科学仪器制造和临床诊断公司)和Avanos Medical, Inc.(公共医疗设备公司)的董事,此前担任Financial Engines, Inc.(投资咨询公司)的董事。她持有哥伦比亚商学院(Columbia Business School)的金融和会计工商管理硕士学位,以及乔治城大学(Georgetown University)的俄语学士学位。
Heidi Kunz,has served as a member of the Board of Directors of Phathom Pharmaceuticals, Inc. since September 2019. She is a member of the Board of Directors of Icosavax, Inc. since May 2021. She has served as Executive Vice President and Chief Financial Officer of Blue Shield of California from 2003 through 2012 and as Executive Vice President and the Chief Financial Officer of Gap, Inc. from 1999 to 2003. Prior thereto, Ms. Kunz served as the Chief Financial Officer of ITT Industries, Inc. from 1995 to 1999. From 1979 to 1995, she held senior financial management positions at General Motors Corporation, including Vice President and Treasurer.
Otis W. Brawley

Otis W. Brawley 自2019年以来,一直担任约翰·霍普金斯大学彭博社肿瘤学和流行病学杰出教授。2007年至2018年,布劳利博士担任美国癌症协会的首席医学和科学官。2001年至2018年,他在埃默里大学担任内科医生、肿瘤学家、血液学、肿瘤学、医学和流行病学教授。自2021年9月以来,Brawley博士在一家公共生物技术公司的InCorporation公司董事会任职。自2021年4月以来,他一直在一家公共生物技术公司的莱尔免疫制药公司董事会任职。自2020年11月以来,他一直在公共生物技术公司PDS Biotechnology Corp的董事会任职。


Otis W. Brawley,has served as the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since 2019. He has served on the board of directors of Incyte Corporation since September 2021. He is on the board of directors of Lyell Immunopharma, Inc. since April 2021. Dr. Brawley is a member of the board of directors of PDS Biotechnology, Inc. since November 2020. Dr. Brawley served as the Chief Medical and Scientific Officer at the American Cancer Society from 2007 to 2018. He served as an Internist and Oncologist and Professor of Hematology, Oncology, Medicine and Epidemiology at Emory University from 2001 to 2018. Dr. Brawley has served on the board of directors of Incyte Corporation, a public biotechnology company, since September 2021. He has served on the board of directors of Lyell Immunopharma, Inc., a public biotechnology company, since April 2021. He has served on the board of directors of PDS Biotechnology Corp, a public biotechnology company, since November 2020.
Otis W. Brawley 自2019年以来,一直担任约翰·霍普金斯大学彭博社肿瘤学和流行病学杰出教授。2007年至2018年,布劳利博士担任美国癌症协会的首席医学和科学官。2001年至2018年,他在埃默里大学担任内科医生、肿瘤学家、血液学、肿瘤学、医学和流行病学教授。自2021年9月以来,Brawley博士在一家公共生物技术公司的InCorporation公司董事会任职。自2021年4月以来,他一直在一家公共生物技术公司的莱尔免疫制药公司董事会任职。自2020年11月以来,他一直在公共生物技术公司PDS Biotechnology Corp的董事会任职。
Otis W. Brawley,has served as the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since 2019. He has served on the board of directors of Incyte Corporation since September 2021. He is on the board of directors of Lyell Immunopharma, Inc. since April 2021. Dr. Brawley is a member of the board of directors of PDS Biotechnology, Inc. since November 2020. Dr. Brawley served as the Chief Medical and Scientific Officer at the American Cancer Society from 2007 to 2018. He served as an Internist and Oncologist and Professor of Hematology, Oncology, Medicine and Epidemiology at Emory University from 2001 to 2018. Dr. Brawley has served on the board of directors of Incyte Corporation, a public biotechnology company, since September 2021. He has served on the board of directors of Lyell Immunopharma, Inc., a public biotechnology company, since April 2021. He has served on the board of directors of PDS Biotechnology Corp, a public biotechnology company, since November 2020.
George A. Scangos

George A. Scangos自从1996年10月担任董事。自2010年7月Scangos博士担任iogen Idec Inc的首席执行官以及董事会成员。从1996年10月到2010年7月,Scangos博士担任总裁以及首席执行官。从1993年9月到1996年10月,Scangos博士担任拜耳生物科技公司(Bayer Corporation)总裁,该公司是一家制药企业,公司主要负责药物的研究、贸易和过程发展、生产制造、工程管理以及质量保证。Scangos博士在多家上市公司董事会担任成员,包括从2003年到2010年在Anadys制药股份有限公司任职,从1997年到2010年在Entelos股份有限公司任职。Scangos博士还在公司之前的子公司,即TaconicArtemis股份有限公司,任职,在2010年前该公司被称为Artemis制药股份有限公司。Scangos博士曾担任加利福尼亚保健协会(CHI)主席、肺结核药物发展计划全球联盟董事会成员、以及BayBio公司董事会主席。Scangos博士现在担任桑特基金会董事;Scangos博士还是加利福尼亚大学和旧金山制药学院董事会成员,以及加利福尼亚大学和戴维斯医学院国家咨询委员会成员。Scangos博士是耶鲁大学Jane Coffin Childs基金博士后奖学金获得者,同时在霍普金斯大学任教。Scangos博士现持有霍普金斯大学生物学兼职教授的任命书。Scangos博士持有康乃尔大学生物学学士学位,以及马赛诸塞大学微生物博士学位。


George A. Scangos,retired as Chief Executive Officer of Vir Biotechnology in April 2023. He has served as a director of Vir Biotechnology, Inc. since January 2017. From May 2023, Dr. Scangos is a director of Voyager Therapeutics, Inc. He is a co-founder and the Chairperson of the Board of Rezo Therapeutics, Inc. since May 2023. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and a director of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer's biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development from 2006 until 2010. He serves on the Board of Advisors of the University of California, San Francisco and is currently an Adjunct Professor of Biology at Johns Hopkins University.
George A. Scangos自从1996年10月担任董事。自2010年7月Scangos博士担任iogen Idec Inc的首席执行官以及董事会成员。从1996年10月到2010年7月,Scangos博士担任总裁以及首席执行官。从1993年9月到1996年10月,Scangos博士担任拜耳生物科技公司(Bayer Corporation)总裁,该公司是一家制药企业,公司主要负责药物的研究、贸易和过程发展、生产制造、工程管理以及质量保证。Scangos博士在多家上市公司董事会担任成员,包括从2003年到2010年在Anadys制药股份有限公司任职,从1997年到2010年在Entelos股份有限公司任职。Scangos博士还在公司之前的子公司,即TaconicArtemis股份有限公司,任职,在2010年前该公司被称为Artemis制药股份有限公司。Scangos博士曾担任加利福尼亚保健协会(CHI)主席、肺结核药物发展计划全球联盟董事会成员、以及BayBio公司董事会主席。Scangos博士现在担任桑特基金会董事;Scangos博士还是加利福尼亚大学和旧金山制药学院董事会成员,以及加利福尼亚大学和戴维斯医学院国家咨询委员会成员。Scangos博士是耶鲁大学Jane Coffin Childs基金博士后奖学金获得者,同时在霍普金斯大学任教。Scangos博士现持有霍普金斯大学生物学兼职教授的任命书。Scangos博士持有康乃尔大学生物学学士学位,以及马赛诸塞大学微生物博士学位。
George A. Scangos,retired as Chief Executive Officer of Vir Biotechnology in April 2023. He has served as a director of Vir Biotechnology, Inc. since January 2017. From May 2023, Dr. Scangos is a director of Voyager Therapeutics, Inc. He is a co-founder and the Chairperson of the Board of Rezo Therapeutics, Inc. since May 2023. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and a director of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer's biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development from 2006 until 2010. He serves on the Board of Advisors of the University of California, San Francisco and is currently an Adjunct Professor of Biology at Johns Hopkins University.
Koh Boon Hwee

Koh Boon Hwee,他担任一个私人股本基金--信任资本基金II开曼有限公司的管理合伙人。2009年1月以来,他担任向阳科技有限公司的非执行主席。此前,从2005年7月到2009年1月,他担任执行董事长兼首席执行官。2010年4月以来,他曾担任杨协成有限公司的非执行董事长。2011年2月以来,担任Rippledot资本顾问私人有限公司的非执行主席。2013年4月以来,担任远东果园有限公司的非执行主席。自2002年2月至2009年8月,他曾担任立通有限公司执行董事。2006年1月至2010年4月任期间,担任星展银行有限公司的主席。从2001年7月至2005年12月,新加坡航空公司主席。从1992年4月至2001年8月,担任新加坡电信的主席。他在其亚太地区的惠普公司工作了十四年。在向阳科技、瑞声科技、立通有限公司、星展银行、新加坡航空公司和新加坡电信担任多个高级职位,这是他拥有很多强有力的领导能力以及操作经验。此外,他在亚太地区拥有丰富的经验,者给董事会带来了知识和见解。他在安捷伦及其前身--惠普有很多经验,在安捷伦董事会9年多以及 在惠普14年。


Koh Boon Hwee,has served as non-Executive Chairperson of Agilent Technologies, Inc. Board since March 2017. As of January 2023, Mr. Koh is the non-Executive Chairman of the Singapore Exchange Ltd. He has been the managing partner of Altara Ventures Pte. Ltd., a venture capital fund, since December 2011. Mr. Koh has served as the non-Executive Chairperson of Sunningdale Tech Ltd., a privately held company, since April 2021. He served as the non-Executive Chairperson and Chief Executive Officer of Sunningdale Tech Ltd., a public company, from January 2009 to March 2021 and served as its Executive Chairperson and Chief Executive Officer from July 2005 to January 2009. He served as the non-Executive Chairperson of Far East Orchard Ltd. from April 2013 to April 2022; served as the non-Executive Chairperson of Yeo Hiap Seng Ltd. from April 2010 to December 2019; as Executive Director of MediaRing Limited from February 2002 to August 2009; Chairperson of DBS Bank Ltd. from January 2006 to April 2010; Chairperson of Singapore Airlines from July 2001 to December 2005 and Chairperson of Singapore Telecom from April 1992 to August 2001. Mr. Koh spent fourteen years with Hewlett-Packard Company in its Asia Pacific region.
Koh Boon Hwee,他担任一个私人股本基金--信任资本基金II开曼有限公司的管理合伙人。2009年1月以来,他担任向阳科技有限公司的非执行主席。此前,从2005年7月到2009年1月,他担任执行董事长兼首席执行官。2010年4月以来,他曾担任杨协成有限公司的非执行董事长。2011年2月以来,担任Rippledot资本顾问私人有限公司的非执行主席。2013年4月以来,担任远东果园有限公司的非执行主席。自2002年2月至2009年8月,他曾担任立通有限公司执行董事。2006年1月至2010年4月任期间,担任星展银行有限公司的主席。从2001年7月至2005年12月,新加坡航空公司主席。从1992年4月至2001年8月,担任新加坡电信的主席。他在其亚太地区的惠普公司工作了十四年。在向阳科技、瑞声科技、立通有限公司、星展银行、新加坡航空公司和新加坡电信担任多个高级职位,这是他拥有很多强有力的领导能力以及操作经验。此外,他在亚太地区拥有丰富的经验,者给董事会带来了知识和见解。他在安捷伦及其前身--惠普有很多经验,在安捷伦董事会9年多以及 在惠普14年。
Koh Boon Hwee,has served as non-Executive Chairperson of Agilent Technologies, Inc. Board since March 2017. As of January 2023, Mr. Koh is the non-Executive Chairman of the Singapore Exchange Ltd. He has been the managing partner of Altara Ventures Pte. Ltd., a venture capital fund, since December 2011. Mr. Koh has served as the non-Executive Chairperson of Sunningdale Tech Ltd., a privately held company, since April 2021. He served as the non-Executive Chairperson and Chief Executive Officer of Sunningdale Tech Ltd., a public company, from January 2009 to March 2021 and served as its Executive Chairperson and Chief Executive Officer from July 2005 to January 2009. He served as the non-Executive Chairperson of Far East Orchard Ltd. from April 2013 to April 2022; served as the non-Executive Chairperson of Yeo Hiap Seng Ltd. from April 2010 to December 2019; as Executive Director of MediaRing Limited from February 2002 to August 2009; Chairperson of DBS Bank Ltd. from January 2006 to April 2010; Chairperson of Singapore Airlines from July 2001 to December 2005 and Chairperson of Singapore Telecom from April 1992 to August 2001. Mr. Koh spent fourteen years with Hewlett-Packard Company in its Asia Pacific region.
Mikael Dolsten

Mikael Dolsten,2010年12月起担任全球研发部的总裁。2010年5月到2010年12月担任全球研究和发展部的高级副总裁,总裁。2009年10月到2010年5月担任Pfize生物治疗药物研发部高级副总裁,总裁。2008年6月到2009年10月担任惠氏的高级副总裁和惠氏研究部的总裁。2008年1月到2008年6月在OrbiMed顾问有限责任公司担任私人股本合作伙伴。


Mikael Dolsten,Chief Scientific Officer, President, Pfizer Research and Development since July 2023. Chief Scientific Officer and President, Worldwide Research, Development and Medical from January 2019 until July 2023. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.
Mikael Dolsten,2010年12月起担任全球研发部的总裁。2010年5月到2010年12月担任全球研究和发展部的高级副总裁,总裁。2009年10月到2010年5月担任Pfize生物治疗药物研发部高级副总裁,总裁。2008年6月到2009年10月担任惠氏的高级副总裁和惠氏研究部的总裁。2008年1月到2008年6月在OrbiMed顾问有限责任公司担任私人股本合作伙伴。
Mikael Dolsten,Chief Scientific Officer, President, Pfizer Research and Development since July 2023. Chief Scientific Officer and President, Worldwide Research, Development and Medical from January 2019 until July 2023. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.
Dow R. Wilson

Dow R. Wilson,自2012年9月起担任瓦里安医疗系统公司董事,自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官,2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月,担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前,曾在通用电气(一家多元化的工业公司)中担任高级管理职务。是萨巴软件公司(电子学习软件供应商)的董事会成员。


Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
Dow R. Wilson,自2012年9月起担任瓦里安医疗系统公司董事,自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官,2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月,担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前,曾在通用电气(一家多元化的工业公司)中担任高级管理职务。是萨巴软件公司(电子学习软件供应商)的董事会成员。
Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
Sue H. Rataj

Sue H. Rataj,女,2008年4月到2011年4月带着与英国石油公司的石油化工业务的全球责任退休期间,她是英国石油公司,(一家全球能源公司)的石油化学产品的首席执行官。在这之前,2007年7月到2008年4月,她在英国石油公司担任了许多高级管理职位,最近是炼油与销售部的小组副总裁。她也是拜耳集团,(一家医疗保健、营养和高科技材料领域的有着核心竞争力的全球企业)的监察委员会成员。在她在英国石油公司的事业期间,她获得了安全和风险管理、会计和财务事务,特别是化学公司的背景的意义重大专业知识。


Sue H. Rataj,was elected as Cabot Corporation's non-executive Chairman of the Board in March 2018. She was Chief Executive, Petrochemicals for BP, a global energy company, until she retired in April 2011. In this role, she held responsibility for all of BP's global petrochemical operations. Prior thereto, Ms. Rataj held a variety of senior management positions with BP, most recently serving as Group Vice President, Health, Safety, Operations and Technology for the Refining and Marketing Segment.
Sue H. Rataj,女,2008年4月到2011年4月带着与英国石油公司的石油化工业务的全球责任退休期间,她是英国石油公司,(一家全球能源公司)的石油化学产品的首席执行官。在这之前,2007年7月到2008年4月,她在英国石油公司担任了许多高级管理职位,最近是炼油与销售部的小组副总裁。她也是拜耳集团,(一家医疗保健、营养和高科技材料领域的有着核心竞争力的全球企业)的监察委员会成员。在她在英国石油公司的事业期间,她获得了安全和风险管理、会计和财务事务,特别是化学公司的背景的意义重大专业知识。
Sue H. Rataj,was elected as Cabot Corporation's non-executive Chairman of the Board in March 2018. She was Chief Executive, Petrochemicals for BP, a global energy company, until she retired in April 2011. In this role, she held responsibility for all of BP's global petrochemical operations. Prior thereto, Ms. Rataj held a variety of senior management positions with BP, most recently serving as Group Vice President, Health, Safety, Operations and Technology for the Refining and Marketing Segment.
Hans E. Bishop

Hans E. Bishop,从2012年5月开始在董事会任职,是Juno医疗公司--肿瘤专科公司CEO。2012年2月-2013年10月,他担任Photothera公司--一家晚期医疗设备公司的首席运营官。2010年1月-2011年9月,他担任Dendreon公司执行副总裁兼首席运营官。2006年12月-2010年1月,他曾在拜耳医疗制药公司担任特效药业务部主管,负责神经类、肿瘤类和血液类产品。他也曾在Chiron、Glaxo Wellcome和史克必成公司担任过各种职位。另外,他曾在一家全球电信服务公司担任过运营执行副主管。2012年1月-2012年11月,他担任Genesis Biopharma公司董事长,该公司是一家生物技术公司。他拥有伦敦布鲁内尔大学化学学士学位。


Hans E. Bishop,is the President, Co-Founder and Co-Chairman of Altos Labs, Inc. since January 2022. He is a member of the Board of Directors of Lyell Immunopharma, Inc. since August 2018. Mr. Bishop has served as Chairman of the Board of Directors of Sana Biotechnology, Inc. since August 2018. He has been a member of the board of directors of Ophirex, Inc. since March 2020. He served as a director of JW (Cayman) Therapeutics Co. Ltd. from September 2013 to December 2022. Mr. Bishop served as Chief Executive Officer of GRAIL, Inc. from June 2019 to October 2021, and served as a member of GRAIL's Board of Directors from August 2016 to October 2021. He served as a member of the Board of Directors of Celgene Corporation from April 2018 to November 2019 when Celgene Corporation was acquired by Bristol-Myers Squibb Company. Mr. Bishop served as President, Chief Executive Officer and a member of the Board of Directors of Juno Therapeutics, Inc. from September 2013 to March 2018 when Juno was acquired by Celgene Corporation. From February 2012 until October 2012, Mr. Bishop was the chief operating officer of Photothera Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Prior to joining Photothera Inc., Mr. Bishop served as executive vice president and chief operating officer at Dendreon Corporation, a publicly traded biopharmaceutical company, from January 2010 to September 2011. Mr. Bishop has also served as the president of the specialty medicine business at Bayer Healthcare Pharmaceuticals Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology and hematology products.
Hans E. Bishop,从2012年5月开始在董事会任职,是Juno医疗公司--肿瘤专科公司CEO。2012年2月-2013年10月,他担任Photothera公司--一家晚期医疗设备公司的首席运营官。2010年1月-2011年9月,他担任Dendreon公司执行副总裁兼首席运营官。2006年12月-2010年1月,他曾在拜耳医疗制药公司担任特效药业务部主管,负责神经类、肿瘤类和血液类产品。他也曾在Chiron、Glaxo Wellcome和史克必成公司担任过各种职位。另外,他曾在一家全球电信服务公司担任过运营执行副主管。2012年1月-2012年11月,他担任Genesis Biopharma公司董事长,该公司是一家生物技术公司。他拥有伦敦布鲁内尔大学化学学士学位。
Hans E. Bishop,is the President, Co-Founder and Co-Chairman of Altos Labs, Inc. since January 2022. He is a member of the Board of Directors of Lyell Immunopharma, Inc. since August 2018. Mr. Bishop has served as Chairman of the Board of Directors of Sana Biotechnology, Inc. since August 2018. He has been a member of the board of directors of Ophirex, Inc. since March 2020. He served as a director of JW (Cayman) Therapeutics Co. Ltd. from September 2013 to December 2022. Mr. Bishop served as Chief Executive Officer of GRAIL, Inc. from June 2019 to October 2021, and served as a member of GRAIL's Board of Directors from August 2016 to October 2021. He served as a member of the Board of Directors of Celgene Corporation from April 2018 to November 2019 when Celgene Corporation was acquired by Bristol-Myers Squibb Company. Mr. Bishop served as President, Chief Executive Officer and a member of the Board of Directors of Juno Therapeutics, Inc. from September 2013 to March 2018 when Juno was acquired by Celgene Corporation. From February 2012 until October 2012, Mr. Bishop was the chief operating officer of Photothera Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Prior to joining Photothera Inc., Mr. Bishop served as executive vice president and chief operating officer at Dendreon Corporation, a publicly traded biopharmaceutical company, from January 2010 to September 2011. Mr. Bishop has also served as the president of the specialty medicine business at Bayer Healthcare Pharmaceuticals Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology and hematology products.

高管简历

中英对照 |  中文 |  英文
Padraig McDonnell

Padraig McDonnell自2021年11月起担任安捷伦科技公司首席商务官兼安捷伦CrossLab集团总裁。2020年5月至2021年11月,他担任安捷伦高级副总裁兼安捷伦CrossLab集团总裁。2016年11月至2020年4月,他担任安捷伦科技公司副总裁兼化学和用品部总经理。在此之前,他曾担任安捷伦科技公司副总裁兼EMEAI实验室解决方案销售总经理。McDonnell此前曾在安捷伦和惠普公司担任过多个职位。


Padraig McDonnell,has served as Agilent Technologies, Inc. Chief Commercial Officer and President, Agilent CrossLab Group since November 2021. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Padraig McDonnell自2021年11月起担任安捷伦科技公司首席商务官兼安捷伦CrossLab集团总裁。2020年5月至2021年11月,他担任安捷伦高级副总裁兼安捷伦CrossLab集团总裁。2016年11月至2020年4月,他担任安捷伦科技公司副总裁兼化学和用品部总经理。在此之前,他曾担任安捷伦科技公司副总裁兼EMEAI实验室解决方案销售总经理。McDonnell此前曾在安捷伦和惠普公司担任过多个职位。
Padraig McDonnell,has served as Agilent Technologies, Inc. Chief Commercial Officer and President, Agilent CrossLab Group since November 2021. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Dominique P. Grau

Dominique P. Grau,2014年8月起,担任本公司的人力资源高级副总裁。2012年5月至2014年8月,他担任全球人力资源副总裁。此前,2006年5月至2012年5月,担任薪酬、福利与人事服务副总裁。此前,他在Agilent、Hewlett-Packard Company担任过各种职务。


Dominique P. Grau,has served as Agilent Technologies, Inc. Senior Vice President, Human Resources and Global Communications since November 2018. From August 2014 to October 2018 he served as Senior Vice President, Human Resources. From May 2012 to August 2014 Mr. Grau served as Vice President, Worldwide Human Resources. Prior to that, he served as Vice President, Compensation, Benefits and HR Services from May 2006 to May 2012. Mr. Grau had previously served in various capacities for Agilent and Hewlett-Packard Company.
Dominique P. Grau,2014年8月起,担任本公司的人力资源高级副总裁。2012年5月至2014年8月,他担任全球人力资源副总裁。此前,2006年5月至2012年5月,担任薪酬、福利与人事服务副总裁。此前,他在Agilent、Hewlett-Packard Company担任过各种职务。
Dominique P. Grau,has served as Agilent Technologies, Inc. Senior Vice President, Human Resources and Global Communications since November 2018. From August 2014 to October 2018 he served as Senior Vice President, Human Resources. From May 2012 to August 2014 Mr. Grau served as Vice President, Worldwide Human Resources. Prior to that, he served as Vice President, Compensation, Benefits and HR Services from May 2006 to May 2012. Mr. Grau had previously served in various capacities for Agilent and Hewlett-Packard Company.
Robert W. McMahon

Robert W. McMahon自2018年8月起担任安捷伦科技公司高级副总裁,自2018年9月起担任首席财务官。他此前于2014年5月至2018年8月在医疗技术公司Hologic, Inc.担任首席财务官。在加入Hologic之前,McMahon先生在强生公司工作了20年,最近担任强生医疗器械和诊断集团Ortho Clinical诊断事业部财务和业务发展全球副总裁。


Robert W. McMahon,has served as Agilent Technologies, Inc. Senior Vice President, Agilent since August 2018 and as Agilent Technologies, Inc. Chief Financial Officer since September 2018. He previously served as the Chief Financial Officer of Hologic, Inc., a medical technology company from May 2014 to August 2018. Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson most recently as Worldwide Vice President of Finance and Business Development for Ortho Clinical Diagnostics a division of Johnson & Johnson's Medical Device and Diagnostics Group. Since July 2023, Mr. McMahon has served as a member of the Board of Directors of Orasure Technologies, Inc.
Robert W. McMahon自2018年8月起担任安捷伦科技公司高级副总裁,自2018年9月起担任首席财务官。他此前于2014年5月至2018年8月在医疗技术公司Hologic, Inc.担任首席财务官。在加入Hologic之前,McMahon先生在强生公司工作了20年,最近担任强生医疗器械和诊断集团Ortho Clinical诊断事业部财务和业务发展全球副总裁。
Robert W. McMahon,has served as Agilent Technologies, Inc. Senior Vice President, Agilent since August 2018 and as Agilent Technologies, Inc. Chief Financial Officer since September 2018. He previously served as the Chief Financial Officer of Hologic, Inc., a medical technology company from May 2014 to August 2018. Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson most recently as Worldwide Vice President of Finance and Business Development for Ortho Clinical Diagnostics a division of Johnson & Johnson's Medical Device and Diagnostics Group. Since July 2023, Mr. McMahon has served as a member of the Board of Directors of Orasure Technologies, Inc.
Rodney Gonsalves

Rodney Gonsalves,自2015年5月起担任公司的副总裁、公司财务控制和会计总监。2009年9月-2015年5月他担任公司不同业务部门(目前在Life Sciences and Applied Markets Group)的副总裁和运营财务总监。2007年1月-2009年8月他担任Investor Relations的副总裁。在担任这个职位之前,他在 Agilent担任不同的职位,包括在Agilent的全球基础设施组织中担任财务总监、公司治理和客户融资,也在光电系统业务部担任财务总监。在加入Agilent之前,他在Hewlett- Packard Co.担任各种各样的职位。Gonsalves先生拥有加州圣克拉拉大学(Santa Clara University in California)工商管理硕士学位。


Rodney Gonsalves,has served as Agilent Technologies, Inc. Vice President, Corporate Controllership and Chief Accounting Officer since May 2015. From September 2009 to May 2015, Mr. Gonsalves served as Vice President and operational CFO for various business groups within the company, most recently for the Life Sciences and Applied Markets Group. Prior to that, Mr. Gonsalves served in various capacities for Agilent, including as vice president of Investor Relations, controller, corporate governance and customer financing in Agilent's Global Infrastructure Organization, and controller for the Photonics Systems Business Unit. Before joining Agilent, Mr. Gonsalves held a variety of positions in finance with Hewlett-Packard Company.
Rodney Gonsalves,自2015年5月起担任公司的副总裁、公司财务控制和会计总监。2009年9月-2015年5月他担任公司不同业务部门(目前在Life Sciences and Applied Markets Group)的副总裁和运营财务总监。2007年1月-2009年8月他担任Investor Relations的副总裁。在担任这个职位之前,他在 Agilent担任不同的职位,包括在Agilent的全球基础设施组织中担任财务总监、公司治理和客户融资,也在光电系统业务部担任财务总监。在加入Agilent之前,他在Hewlett- Packard Co.担任各种各样的职位。Gonsalves先生拥有加州圣克拉拉大学(Santa Clara University in California)工商管理硕士学位。
Rodney Gonsalves,has served as Agilent Technologies, Inc. Vice President, Corporate Controllership and Chief Accounting Officer since May 2015. From September 2009 to May 2015, Mr. Gonsalves served as Vice President and operational CFO for various business groups within the company, most recently for the Life Sciences and Applied Markets Group. Prior to that, Mr. Gonsalves served in various capacities for Agilent, including as vice president of Investor Relations, controller, corporate governance and customer financing in Agilent's Global Infrastructure Organization, and controller for the Photonics Systems Business Unit. Before joining Agilent, Mr. Gonsalves held a variety of positions in finance with Hewlett-Packard Company.
Michael Tang

Michael Tang于2016年1月起担任安捷伦科技公司高级副总裁、总法律顾问兼秘书。2015年5月至2016年1月,他担任副总裁、助理总法律顾问和秘书;2013年11月至2015年4月,他担任副总裁、助理总法律顾问和助理秘书。2012年3月至2013年10月,他在安捷伦的企业发展集团担任业务发展经理。在此之前,Tang先生曾在安捷伦的法律部门担任过各种职务。在加入安捷伦之前,Tang先生曾任职于加州律师事务所Wilson Sonsini Goodrich & Rosati和加州律师事务所Fenwick & West LLP。


Michael Tang,has served as Agilent Technologies, Inc. Senior Vice President, General Counsel and Secretary since January 2016. From May 2015 to January 2016 he served as Vice President, Assistant General Counsel and Secretary and from November 2013 to April 2015 he served as Vice President, Assistant General Counsel and Assistant Secretary. From March 2012 to October 2013 he served as Business Development Manager in Agilent's Corporate Development group. Prior to that, Mr. Tang served in various capacities in Agilent's legal department. Before joining Agilent, Mr. Tang worked at Wilson Sonsini Goodrich & Rosati, a California law firm and Fenwick & West LLP, a California law firm.
Michael Tang于2016年1月起担任安捷伦科技公司高级副总裁、总法律顾问兼秘书。2015年5月至2016年1月,他担任副总裁、助理总法律顾问和秘书;2013年11月至2015年4月,他担任副总裁、助理总法律顾问和助理秘书。2012年3月至2013年10月,他在安捷伦的企业发展集团担任业务发展经理。在此之前,Tang先生曾在安捷伦的法律部门担任过各种职务。在加入安捷伦之前,Tang先生曾任职于加州律师事务所Wilson Sonsini Goodrich & Rosati和加州律师事务所Fenwick & West LLP。
Michael Tang,has served as Agilent Technologies, Inc. Senior Vice President, General Counsel and Secretary since January 2016. From May 2015 to January 2016 he served as Vice President, Assistant General Counsel and Secretary and from November 2013 to April 2015 he served as Vice President, Assistant General Counsel and Assistant Secretary. From March 2012 to October 2013 he served as Business Development Manager in Agilent's Corporate Development group. Prior to that, Mr. Tang served in various capacities in Agilent's legal department. Before joining Agilent, Mr. Tang worked at Wilson Sonsini Goodrich & Rosati, a California law firm and Fenwick & West LLP, a California law firm.
Phil Binns

Phil Binns,自2023年9月起担任安捷伦科技公司安捷伦高级副总裁兼生命科学和应用市场集团总裁。2015年1月至2023年9月,Binns先生担任安捷伦光谱和真空产品事业部副总裁兼总经理。从2010年到2015年1月,Binns先生担任安捷伦副总裁兼光谱部门总经理。在2010年加入安捷伦之前,他自1994年起在瓦里安的全球业务部门担任过多个职位,包括2004年被任命为瓦里安环太平洋地区外勤业务总经理。


Phil Binns,has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Life Sciences and Applied Markets Group since September 2023. From January 2015 to September 2023, Mr. Binns served as Agilent Vice President and General Manager for the Spectroscopy and Vacuum Products Division. From 2010 to January 2015, Mr Binns served as Agilent Vice President and General Manager for the Spectroscopy Division. Prior to joining Agilent in 2010, he held various positions in Varian's global operations since 1994, including his appointment as General Manager of Varian's field operations in 2004 for the Pacific Rim.
Phil Binns,自2023年9月起担任安捷伦科技公司安捷伦高级副总裁兼生命科学和应用市场集团总裁。2015年1月至2023年9月,Binns先生担任安捷伦光谱和真空产品事业部副总裁兼总经理。从2010年到2015年1月,Binns先生担任安捷伦副总裁兼光谱部门总经理。在2010年加入安捷伦之前,他自1994年起在瓦里安的全球业务部门担任过多个职位,包括2004年被任命为瓦里安环太平洋地区外勤业务总经理。
Phil Binns,has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Life Sciences and Applied Markets Group since September 2023. From January 2015 to September 2023, Mr. Binns served as Agilent Vice President and General Manager for the Spectroscopy and Vacuum Products Division. From 2010 to January 2015, Mr Binns served as Agilent Vice President and General Manager for the Spectroscopy Division. Prior to joining Agilent in 2010, he held various positions in Varian's global operations since 1994, including his appointment as General Manager of Varian's field operations in 2004 for the Pacific Rim.
Henrik Ancher Jensen

Henrik Ancher Jensen,自2013年9月以来,他担任安捷伦的高级副总裁以及负责订单履行的总裁。2012年9月至2013年9月,他担任全球产品供应、诊断及基因组学集团的副总裁。2010年9月至2012年9月,他担任阿古A / S丹麦诊断公司负责全球运营的公司副总裁。2006年至2010年9月,他担任供应链的副总裁兼首席信息官。在加入Dako公司之前,他花了15年多的时间在汉森、德勤咨询和NVE公司担任高级管理以及管理咨询职位。


Henrik Ancher Jensen,has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Order Fulfillment and Supply chain since September 2013. From September 2012 to September 2013, Mr. Ancher-Jensen served as Agilent Technologies, Inc. Vice President, Global Product Supply, Diagnostics and Genomics Group. From September 2010 to September 2012 he served as Corporate Vice President, Global Operations of Dako A/S, a Danish diagnostics company, and as Dako's Vice President, Supply Chain and Chief Information Officer from 2006 to September 2010. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE.
Henrik Ancher Jensen,自2013年9月以来,他担任安捷伦的高级副总裁以及负责订单履行的总裁。2012年9月至2013年9月,他担任全球产品供应、诊断及基因组学集团的副总裁。2010年9月至2012年9月,他担任阿古A / S丹麦诊断公司负责全球运营的公司副总裁。2006年至2010年9月,他担任供应链的副总裁兼首席信息官。在加入Dako公司之前,他花了15年多的时间在汉森、德勤咨询和NVE公司担任高级管理以及管理咨询职位。
Henrik Ancher Jensen,has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Order Fulfillment and Supply chain since September 2013. From September 2012 to September 2013, Mr. Ancher-Jensen served as Agilent Technologies, Inc. Vice President, Global Product Supply, Diagnostics and Genomics Group. From September 2010 to September 2012 he served as Corporate Vice President, Global Operations of Dako A/S, a Danish diagnostics company, and as Dako's Vice President, Supply Chain and Chief Information Officer from 2006 to September 2010. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE.